Market Size
The global Immuno-Oncology (IO)-thematic intelligence market reached USD 7.78 billion in 2025 and is expected to reach USD 21.53 billion by 2033, growing at a CAGR of 14.8% from 2026 to 2033.
Thematic intelligence in immuno-oncology involves systematically analyzing key themes, trends, and factors influencing cancer treatment through immune system modulation, utilizing diverse insights from various sources to gain a holistic view of the field.
Immuno-oncology agents have significantly improved cancer treatment, offering hope to patients with limited options. With over 700 novel agents in clinical development, including cell therapies and checkpoint modulators, continued investment in IO research is crucial for further advancements and improved clinical outcomes.
Market Scope
| Metrics | Details |
| CAGR | 14.8% |
| Market Size Available for Years | 2025-2033 |
| Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Type, Indication, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rise in technological advancements
The rise in technological advancements in immunotherapies is one of the driving factors that help the market to grow during the forecast period. For instance, an area of innovation in India is the use of personalized medicine in immuno-oncology. This approach involves using genetic information about a patient’s tumour to select the most appropriate IO treatment for that individual. Research is being conducted to develop methods for identifying which patients are most likely to respond to immunotherapy drugs and to understand the mechanisms behind the clinical response.
Some of these path-breaking innovations have a significant artificial intelligence (AI) / machine learning (ML) component. AI is also being leveraged for assessing new and better combination therapies which involve using more than one type of existing treatment in conjunction with immunotherapy for better outcomes.
Furthermore, the global immuno-oncology (io)-thematic intelligence is also driven by various other factors like a rise in clinical trials and approval of IO therapies, a rise in demand for combination therapies and others helping the market to grow during the forecast period.
Overuse of combination therapies
The widespread use of combination therapies can make clinical trial design more complex, especially if no combination partner is currently approved or if clinical trials require acquisition or additional costs for the combination partner. The introduction of these combination therapies is expected to increase treatment costs, which may require new models for working with payers and demonstrating cost-effectiveness.
Recent Developments
February 2026: Across North America, Europe, and Asia Pacific, rapid integration of AI-driven analytics and real-world data significantly accelerated growth in the Immuno-Oncology (IO)-thematic intelligence market, enabling improved patient stratification and clinical trial optimization.
January 2026: Advancements in precision medicine, biomarker-driven therapies, and combination immunotherapies enhanced treatment effectiveness, particularly in solid tumors and difficult-to-treat cancers.
December 2025: Leading companies such as Thermo Fisher Scientific, Merck & Co., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, and AstraZeneca expanded immuno-oncology pipelines and strengthened investments in AI-enabled drug discovery and clinical research platforms.
November 2025: Increasing adoption of next-generation therapies including CAR-T, TCR-T, bispecific antibodies, and antibody-drug conjugates (ADCs) significantly boosted innovation in cancer immunotherapy.
October 2025: Growing focus on personalized cancer vaccines and neoantigen-based therapies accelerated development of targeted treatments tailored to individual patient profiles.
September 2025: In the United States, strong clinical trial activity, regulatory support, and high R&D investments significantly drove market expansion and technological leadership.
August 2025: In China, Japan, and India, increasing oncology research, rising cancer prevalence, and expanding healthcare infrastructure accelerated regional adoption of IO intelligence platforms.
July 2025: Rising number of clinical trials and a robust pipeline of immuno-oncology agents, including checkpoint inhibitors and cell therapies, supported continuous innovation and long-term global market growth.
Market Competitive Landscape
The major global players in the market include Thermofisher Scientific, Merck & Co, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis, Eli Lilly, Regeneron Pharmaceuticals, GSK, and Fresenius Kabi, among others.
Why Purchase the Report?
- To visualize the global immuno-oncology (io)-thematic intelligence market segmentation based on type, indication, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analysing trends and co-development.
- Excel data sheet with numerous data points of immuno-oncology (IO)-thematic intelligence market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global immuno-oncology (IO)-thematic intelligence market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
